Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

NCT01211691 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped KaloBios to Wind Down Operations

Conditions

Myelodysplastic Syndrome (MDS)
Myelofibrosis (MF)

Interventions

DRUG: KB004, Monoclonal Antibody

Sponsor

Humanigen, Inc.